The MetaHeps® technology is based on the generation of hepatocyte-like cells from peripheral blood monocytes (United States Patent 8,858,934, [2014]; EU Patent 11 743 234.4 [2015]; Japan Patent 2013-523628 [2016])



These cells show donor specific characteristics and allow patient centric individualised toxicity testing. The generation process is standardised, without genetic modifications and under serum-free conditions. All that is required is a patient's blood sample (whole EDTA-blood). This allows testing in all patient groups (including children).




This unique technology for individualized patient testing is only necessary in cases of iDILI-suspicion. Samples of tolerators or healthy donors can be used to refine the system and ensure the patients individual susceptibility.


Our Assets